Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 15.11 Billion KRW | -41.67% |
| 2022 | 51.83 Billion KRW | 6.46% |
| 2021 | 48.44 Billion KRW | 15.66% |
| 2020 | 38.46 Billion KRW | 8.68% |
| 2019 | 39.08 Billion KRW | 71.36% |
| 2018 | 20.32 Billion KRW | -28.81% |
| 2017 | 97.7 Billion KRW | 3.48% |
| 2016 | 33.04 Billion KRW | 31.63% |
| 2015 | 25.33 Billion KRW | 41.29% |
| 2014 | 17.4 Billion KRW | 11.33% |
| 2013 | 16.26 Billion KRW | 45.8% |
| 2012 | 11.15 Billion KRW | 3.64% |
| 2011 | 10.77 Billion KRW | -19.2% |
| 2010 | 13.34 Billion KRW | -0.13% |
| 2009 | 13.76 Billion KRW | 226.2% |
| 2008 | -10.56 Billion KRW | -234.32% |
| 2007 | 8.01 Billion KRW | -26.89% |
| 2006 | 10.73 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 4.43 Billion KRW | -10.64% |
| 2024 Q1 | 4.43 Billion KRW | -52.35% |
| 2023 Q4 | 11.59 Billion KRW | -78.0% |
| 2023 Q1 | 42.21 Billion KRW | 364.13% |
| 2023 Q3 | 52.71 Billion KRW | 4.72% |
| 2023 Q2 | 50.33 Billion KRW | 19.23% |
| 2023 FY | - KRW | -41.67% |
| 2022 Q1 | 16.02 Billion KRW | -4.58% |
| 2022 FY | - KRW | 6.46% |
| 2022 Q4 | 9.09 Billion KRW | -44.69% |
| 2022 Q3 | 16.44 Billion KRW | 37.37% |
| 2022 Q2 | 11.97 Billion KRW | -25.32% |
| 2021 Q2 | 9.38 Billion KRW | -0.45% |
| 2021 Q1 | 9.42 Billion KRW | -14.38% |
| 2021 FY | - KRW | 15.66% |
| 2021 Q4 | 16.8 Billion KRW | 6.35% |
| 2021 Q3 | 15.79 Billion KRW | 68.31% |
| 2020 Q2 | 10.67 Billion KRW | 2.99% |
| 2020 Q4 | 11.01 Billion KRW | -23.83% |
| 2020 Q3 | 14.45 Billion KRW | 35.43% |
| 2020 Q1 | 10.36 Billion KRW | 47.17% |
| 2020 FY | - KRW | 8.68% |
| 2019 Q1 | 12.83 Billion KRW | 1279.73% |
| 2019 FY | - KRW | 71.36% |
| 2019 Q4 | 7.04 Billion KRW | -39.74% |
| 2019 Q3 | 11.68 Billion KRW | 0.57% |
| 2019 Q2 | 11.62 Billion KRW | -9.49% |
| 2018 Q1 | 13.38 Billion KRW | 49.8% |
| 2018 FY | - KRW | -28.81% |
| 2018 Q2 | 8.35 Billion KRW | -37.57% |
| 2018 Q3 | 3.77 Billion KRW | -54.84% |
| 2018 Q4 | -1.08 Billion KRW | -128.83% |
| 2017 Q3 | 8.13 Billion KRW | -5.74% |
| 2017 FY | - KRW | 3.48% |
| 2017 Q1 | 9.12 Billion KRW | 4.14% |
| 2017 Q2 | 8.63 Billion KRW | -5.35% |
| 2017 Q4 | 8.93 Billion KRW | 9.85% |
| 2016 Q3 | 7.81 Billion KRW | 15.88% |
| 2016 Q4 | 8.75 Billion KRW | 12.09% |
| 2016 Q1 | 10.08 Billion KRW | 0.0% |
| 2016 Q2 | 6.74 Billion KRW | -33.11% |
| 2016 FY | - KRW | 31.63% |
| 2015 Q3 | 5.45 Billion KRW | -37.61% |
| 2015 Q1 | 6.75 Billion KRW | 37.46% |
| 2015 FY | - KRW | 41.29% |
| 2015 Q2 | 8.74 Billion KRW | 29.55% |
| 2014 Q2 | 3.35 Billion KRW | -41.93% |
| 2014 Q1 | 5.77 Billion KRW | 46.92% |
| 2014 FY | - KRW | 11.33% |
| 2014 Q4 | 4.91 Billion KRW | 57.46% |
| 2014 Q3 | 3.11 Billion KRW | -6.94% |
| 2013 FY | - KRW | 45.8% |
| 2013 Q1 | 2.89 Billion KRW | 16.23% |
| 2013 Q2 | 3.15 Billion KRW | 9.07% |
| 2013 Q3 | 2 Billion KRW | -36.28% |
| 2013 Q4 | 3.92 Billion KRW | 95.45% |
| 2012 Q1 | 2.79 Billion KRW | 17.74% |
| 2012 Q2 | 2.68 Billion KRW | -4.08% |
| 2012 Q3 | 1.72 Billion KRW | -35.62% |
| 2012 FY | - KRW | 3.64% |
| 2012 Q4 | 2.48 Billion KRW | 44.16% |
| 2011 Q2 | 2.52 Billion KRW | -31.82% |
| 2011 Q1 | 3.7 Billion KRW | 7.09% |
| 2011 FY | - KRW | -19.2% |
| 2011 Q4 | 2.37 Billion KRW | -22.07% |
| 2011 Q3 | 3.04 Billion KRW | 20.49% |
| 2010 Q3 | 2.58 Billion KRW | -27.68% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | - KRW | -0.13% |
| 2010 Q2 | 3.57 Billion KRW | 0.0% |
| 2010 Q4 | 3.46 Billion KRW | 34.06% |
| 2009 Q1 | -7.84 Billion KRW | -331.04% |
| 2009 FY | - KRW | 226.2% |
| 2009 Q4 | 3.61 Billion KRW | 43.49% |
| 2009 Q3 | 2.52 Billion KRW | 40.32% |
| 2009 Q2 | 1.79 Billion KRW | 122.89% |
| 2008 Q4 | 3.39 Billion KRW | 277.46% |
| 2008 FY | - KRW | -234.32% |
| 2008 Q3 | -1.91 Billion KRW | 54.49% |
| 2008 Q2 | -4.2 Billion KRW | -536.42% |
| 2008 Q1 | 963.95 Million KRW | -51.34% |
| 2007 Q2 | 2.35 Billion KRW | 0.0% |
| 2007 Q4 | 1.98 Billion KRW | -22.98% |
| 2007 FY | - KRW | -26.89% |
| 2007 Q3 | 2.57 Billion KRW | 9.21% |
| 2006 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -211.181% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 89.305% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 123.609% |
| HANDOK Inc. | 35.06 Billion KRW | 56.887% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 1558.48% |
| Yuhan Corporation | 127.43 Billion KRW | 88.136% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 59.707% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 169.709% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 95.324% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -202.951% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -341.928% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -234.001% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 57.397% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -211.181% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 181.845% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -130.638% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 130.671% |
| JW Holdings Corporation | 187.88 Billion KRW | 91.953% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 129.511% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 94.67% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 83.055% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 140.786% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -14.449% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -27.819% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 18.958% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -211.181% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 72.499% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 90.833% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 83.055% |
| Yuhan Corporation | 127.43 Billion KRW | 88.136% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 54.838% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -97.628% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 80.373% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 83.055% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 58.732% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 78.641% |
| CKD Bio Corp. | -1.63 Billion KRW | 1027.247% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 69.638% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 53.57% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 58.929% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 140.786% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 75.727% |
| Boryung Corporation | 114.28 Billion KRW | 86.772% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 149.457% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 0.0% |
| JW Lifescience Corporation | 50.82 Billion KRW | 70.257% |